REMAGUS 02试验长期结局:局部晚期乳腺癌新辅助化疗联合或不联合塞来昔布或曲妥珠单抗的多中心随机II期研究
REMAGUS-02多中心随机II期试验纳入2004至2007年340例II-III期乳腺癌患者,HER2阴性者随机接受新辅助EC-T联合或不联合塞来昔布,HER2阳性者联合或不联合曲妥珠单抗。中位随访94.4个月,塞来昔布未带来无病生存获益,新辅助曲妥珠单抗未转化为无病生存或总生存获益,腋窝病理完全缓解可能是HER2阳性人群更相关的生存替代指标。
要点
- HER2阴性组加用塞来昔布未带来无病生存获益。
- HER2阳性组新辅助曲妥珠单抗未转化为无病生存或总生存获益。
- 腋窝病理完全缓解与HER2阳性组无病生存相关(HR=0.44)。
核心结论
- 塞来昔布联合新辅助化疗在HER2阴性乳腺癌患者中既未提高病理完全缓解率也未带来生存获益。
- 孕激素受体阴性是主要预后因素。
- 新辅助曲妥珠单抗提高病理完全缓解率但未转化为无病生存或总生存获益,与仅辅助曲妥珠单抗相比。
- 腋窝病理完全缓解可能是HER2阳性人群比乳腺病理完全缓解更相关的生存替代指标。
- 回顾性比较显示HER2阳性肿瘤患者结局优于HER2阴性乳腺癌患者,体现曲妥珠单抗对乳腺癌自然史的影响。
研究设计与样本
- REMAGUS-02为多中心随机II期试验,2004年至2007年纳入340例II-III期乳腺癌患者。
- HER2阴性者(n=220)随机接受新辅助EC-T(四周期表柔比星-环磷酰胺后四周期多西他赛)联合或不联合塞来昔布。
- HER2阳性者(n=120)随机接受新辅助EC-T联合或不联合曲妥珠单抗。
- 自2005年9月起,所有HER2阳性乳腺癌患者接受辅助曲妥珠单抗(n=106)。
主要发现
- 中位随访近8年(94.4个月,范围20-127个月)。
- HER2阴性亚组中,加用塞来昔布与无病生存获益无关。
- 有利因素为较小肿瘤尺寸、孕激素受体状态表达和病理完全缓解。
- HER2阳性人群中,新辅助曲妥珠单抗与无病生存获益无关。
- HER2阳性组中腋窝病理完全缓解是唯一与无病生存相关的预后因素(HR=0.44,95%CI=0.2-0.97,p=0.035)。
关键数值与推荐
- HER2阳性乳腺癌患者的无病生存和总生存显著高于HER2阴性乳腺癌患者(HR=0.58,95%CI=0.36-0.92,p=0.021)。
- HER2阳性组中腋窝病理完全缓解与无病生存相关(HR=0.44,95%CI=0.2-0.97,p=0.035)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The REMAGUS-02 multicenter randomised phase II trial showed that the addition to neoadjuvant chemotherapy (NAC) of trastuzumab in patients with localised HER2-positive breast cancer (BC) increased the pathological complete response (pCR) rate and that the addition of celecoxib in HER2-negative cases did not increase the pCR rate. We report here the long-term follow-up results for disease-free survival (DFS) and overall survival (OS). PATIENTS AND METHODS: From 2004 to 2007, 340 stage II-III BC patients were randomly assigned to receive neoadjuvant EC-T (four cycles of epirubicin-cyclophosphamide followed by four cycles of docetaxel) +/- celecoxib in HER2-negative cases (n = 220) and ± trastuzumab in HER2-positive cases (n = 120). From September 2005, all patients with HER2-positive BC received adjuvant T (n = 106). RESULTS: Median follow-up was nearly 8 years (94.4 months, 20-127 m). In the HER2-negative subgroup, addition of celecoxib was not associated with a DFS benefit. Favourable factors were smaller tumour size, expression of progesterone receptor status (PgR) and pCR. In the HER2-positive population, neoadjuvant trastuzumab was not associated with a DFS benefit. Axillary pCR was the only prognostic factor associated with DFS in this group [HR = 0.44, 95% CI = 0.2-0.97], p = 0.035]. To note, DFS and OS were significantly higher in the HER2-positive than in HER2-negative BC patients (HR = 0.58 [0.36-0.92], p = 0.021). CONCLUSION: Celecoxib combined with NAC provided neither pCR nor survival benefit in patients with HER2-negative BC. Absence of PgR is a major prognostic factor. Neoadjuvant trastuzumab increased pCR rates without translation into a DFS or OS benefit compared with adjuvant trastuzumab only. Axillary pCR could be a more relevant surrogate of survival than in the breast in HER2-positive population. A retrospective comparison shows that patients with HER2-positive tumours have a better outcome than HER2-negative BC patients showing the impact of trastuzumab on the natural history of BC.
引用
- Giacchetti S, Hamy AS, Delaloge S, et al. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status. Eur J Cancer. 2017. PMID: 28279941. doi:10.1016/j.ejca.2017.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。